JP Morgan Chase
IMNP

JP Morgan Chase’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

JP Morgan Chase’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,510
Closed -$7K – 5775
2017
Q4 		$7K Buy
+11,510
New +$11K ﹤0.01% 5300

Other funds holding IMNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JP Morgan Chase's IMNP Position: Q1 2018 in Review

JP Morgan Chase sold out of Immune Pharmaceuticals Inc. (IMNP) in Q1 2018, closing a stake of 11,510 shares — an estimated $7K sold.

JP Morgan Chase first reported a position in IMNP in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 17 funds tracked by Wall St. Rank hold IMNP as of Q1 2018.

  • JP Morgan Chase reported no remaining Immune Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • JP Morgan Chase sold 11,510 Immune Pharmaceuticals Inc. shares in Q1 2018, an estimated $7K.
  • JP Morgan Chase first reported a position in Immune Pharmaceuticals Inc. in Q4 2017 and held it in 1 quarter.
  • JP Morgan Chase's Immune Pharmaceuticals Inc. position peaked at $7K in Q4 2017.
  • 17 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q1 2018.

Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.